TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7817261

Group type: EXPERIMENTAL
Intervention: Treatment for exophytic warts or clinical symptoms (n = 55)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Follow-up only (n = 263; 150 with HPV suggestive lesions, 113 without)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Condom use (anamnestic)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: ISH-positivity
Number of subjects: 318
Study: 3061032

Group type: EXPERIMENTAL
Intervention: Indoramin (initial dose 50 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propranolol (initial dose 80 mg/d)
Number of subjects: 50
Study: 30563555

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 28052413

Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Number of subjects: 511

Group type: COMPARATOR
Intervention: Iron sucrose
Number of subjects: 511
Study: 25497243

Group type: EXPERIMENTAL
Intervention: 3.0-T cardiovascular magnetic resonance-guided care
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: single-photon emission computed tomography-guided care
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: National Institute for Health and Care Excellence guidelines-based management
Number of subjects: 1200

Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 1200
Study: 24321138

Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (PM1300 μg/m(3))
Number of subjects: 18

Group type: COMPARATOR
Intervention: Filtered air exposure (PM12 μg/m(3))
Number of subjects: 18
Study: 20597264

Group type: EXPERIMENTAL
Intervention: Rheumatological examination for RA diagnosis
Number of subjects: 3420

Group type: COMPARATOR
Intervention: Self-reported RA diagnosis before examination
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Final diagnosis by specialist
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Awareness of RA diagnosis among identified patients
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Awareness of diagnosis in patients with less than one-year complaints
Number of subjects: 3420

Group type: EXPERIMENTAL
Intervention: Awareness of diagnosis in patients with long-term complaints
Number of subjects: 3420
Study: 18203766

Group type: EXPERIMENTAL
Intervention: Pre-operative long saphenous vein mapping (n=31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 61
Study: 16647301

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) at doses of 50, 75, and 100 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Withdrawal from TPM and substitution with older antiepileptic drugs
Number of subjects: 47
Study: 14521743

Group type: EXPERIMENTAL
Intervention: Naphtoquine (1,000 mg single daily dosage for one day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mefloquine (750 mg single dosage)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Artesunate (600 mg total dosage for five days, doubling dosage on the first day)
Number of subjects: 90
Study: 10744189

Group type: EXPERIMENTAL
Intervention: Breathing out into water exercise during subtotal immersion (9 patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Breathing exercises without breathing out into water exercise (8 patients)
Number of subjects: 17
Study: 8634389

Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest (HCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass (LFB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCA with longer duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-stat strategy during cooling before HCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: pH-stat strategy
Number of subjects: 0
Study: 1595791

Group type: EXPERIMENTAL
Intervention: Trained residents providing brief structured smoking cessation advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard advice
Number of subjects: 0
Study: 6233176

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) + Dexamethasone (DEX) 0.5 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 50 mg on days 5 to 9
Number of subjects: 64
Study: 30808567

Group type: EXPERIMENTAL
Intervention: RV5 (pentavalent rotavirus vaccine)
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4040

Group type: EXPERIMENTAL
Intervention: RV5 (in concomitant use)
Number of subjects: 4040

Group type: COMPARATOR
Intervention: Placebo (in concomitant use)
Number of subjects: 4040
Study: 28875470

Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP)
Number of subjects: 221
Study: 26908117

Group type: EXPERIMENTAL
Intervention: Motivational interviewing style intervention
Number of subjects: 282

Group type: COMPARATOR
Intervention: Mail-out recruitment strategy
Number of subjects: 282
Study: 25110338

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative regression models
Number of subjects: 42839

Group type: COMPARATOR
Intervention: Lowest-risk decile (mean STS-PROM of 0.6%)
Number of subjects: 42839

Group type: COMPARATOR
Intervention: Highest-risk decile (mean STS-PROM 19%)
Number of subjects: 42839

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 42839

Group type: EXPERIMENTAL
Intervention: Overall CABG procedure
Number of subjects: 42839
Study: 22798531

Group type: EXPERIMENTAL
Intervention: 15 mL of mepivacaine 1.5% followed by 15 mL of bupivacaine 0.5% (group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 15 mL of bupivacaine 0.5% followed by 15 mL of mepivacaine 1.5% (group B)
Number of subjects: 64
Study: 21218459

Group type: EXPERIMENTAL
Intervention: Palonosetron on Days 1-5
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Palonosetron on Days 1, 3, and 5
Number of subjects: 143

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 143
Study: 17633481

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Posterior fixation
Number of subjects: 42
Study: 16242558

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise rehabilitation (40% of maximal exercise capacity)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-intensity exercise rehabilitation (80% of maximal exercise capacity)
Number of subjects: 64
Study: 11933731

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10438706

Group type: EXPERIMENTAL
Intervention: ATRA+CT
Number of subjects: 413

Group type: COMPARATOR
Intervention: ATRA-->CT
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Continuous maintenance CT
Number of subjects: 413

Group type: COMPARATOR
Intervention: No CT
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Intermittent ATRA
Number of subjects: 413

Group type: COMPARATOR
Intervention: No ATRA
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Maintenance CT
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Maintenance ATRA
Number of subjects: 413
Study: 7608278

Group type: EXPERIMENTAL
Intervention: iv dexamethasone (2.0‐16.0 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dexamethasone treatment
Number of subjects: 12
Study: 2222952

Group type: EXPERIMENTAL
Intervention: felodipine 10 mg extended release once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: felodipine
Number of subjects: 12
Study: 7446514

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study: 31707068

Group type: EXPERIMENTAL
Intervention: Intervention exposure after randomisation
Number of subjects: 10
Study: 28404834

Group type: EXPERIMENTAL
Intervention: Mama SASHA intervention (enhanced nutrition counseling, community-based maternal support groups, vouchers for OFSP vine cuttings)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Mama SASHA intervention
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (clinic-based nutrition counseling only)
Number of subjects: 505
Study: 25690418

Group type: EXPERIMENTAL
Intervention: 30 g/day heat-stabilized rice bran (SRB) for 28 days
Number of subjects: 7
Study: 22548586

Group type: EXPERIMENTAL
Intervention: PDT followed by SRP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: KTP laser followed by SRP
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 24
Study: 21327796

Group type: EXPERIMENTAL
Intervention: Salbutamol 10 μg/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Salbutamol 20 μg/min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study: 19091807

Group type: EXPERIMENTAL
Intervention: Website use
Number of subjects: 228

Group type: COMPARATOR
Intervention: Web pages related to behavioral feedback and communications
Number of subjects: 228
Study: 16684437

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Armodafinil 250 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Armodafinil combined groups
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg and 250 mg
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 15614594

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (N=65)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list control (N=35)
Number of subjects: 100
Study: 11379973

Group type: EXPERIMENTAL
Intervention: Intervention groups (specific details not provided)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Assessment process
Number of subjects: 45
Study: 8994756

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam (A/S)
Number of subjects: 90

Group type: COMPARATOR
Intervention: imipenem/cilastatin (I/C)
Number of subjects: 90
Study: 8430676

Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency (CRI) patients
Number of subjects: 360
Study: 3115786

Group type: EXPERIMENTAL
Intervention: DFMO (1.7 g/m sq. t.i.d. added to conventional chemotherapy)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional chemotherapy only (control group of 32 patients)
Number of subjects: 38
Study: 29362444

Group type: EXPERIMENTAL
Intervention: Active minocycline (100 mg b.i.d.) + active aspirin (81 mg b.i.d.) (M + A)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Active minocycline + placebo aspirin (M + P)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Placebo-minocycline + active aspirin (A + P)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo-minocycline + placebo aspirin (P + P)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 99
Study: 27599265

Group type: EXPERIMENTAL
Intervention: In-person help to access services with follow-up telephone calls (navigation intervention)
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Written information on relevant community services (active control)
Number of subjects: 1809
Study: 24033822

Group type: EXPERIMENTAL
Intervention: 2% niacinamide + 2% tranexamic acid (TXA) cream (test formulation; n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle control cream (n = 21)
Number of subjects: 42
Study: 22401534

Group type: EXPERIMENTAL
Intervention: Anticipated Regret (AR) group
Number of subjects: 14520

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB) group
Number of subjects: 14520

Group type: COMPARATOR
Intervention: Questionnaire Control (QC) group
Number of subjects: 14520

Group type: COMPARATOR
Intervention: No Questionnaire Control (NQC) group
Number of subjects: 14520
Study: 20721920

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/d)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 19026251

Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (MAS) (12.5 mg to 75 mg)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (MAS)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 16830947

Group type: EXPERIMENTAL
Intervention: Automated left ventricular segmentation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experienced radiologists (manual method)
Number of subjects: 0
Study: 12663706

Group type: COMPARATOR
Intervention: No adjuvant therapy or a single cycle of perioperative chemotherapy for node-negative disease (1,275 women)
Number of subjects: 5352

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy of at least 3 months' duration and/or tamoxifen for node-positive disease (4,077 women)
Number of subjects: 5352
Study: 10972581

Group type: EXPERIMENTAL
Intervention: Diet therapy for 3 months
Number of subjects: 2906
Study: 9370178

Group type: EXPERIMENTAL
Intervention: Sequential therapy with anti-thymocyte globulin (ATG) 20 mg/kg/d for 7 to 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: CsA 8 mg/kg/d started immediately before surgery with diltiazem 60 mg sustained release twice daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sequential therapy with anti-thymocyte globulin (ATG)
Number of subjects: 100
Study: 1583321

Group type: EXPERIMENTAL
Intervention: Single 5 x 10(8) cfu dose
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Single 5 x 10(9) cfu dose
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Second 5 x 10(9) cfu dose one week later
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Increasing vaccine dose to 5 x 10(9) cfu
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Baseline vibriocidal titer
Number of subjects: 324
Study: 3896281

Group type: EXPERIMENTAL
Intervention: Nicardipine (average daily dose 84 mg, range 40-160 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28144988

Group type: EXPERIMENTAL
Intervention: Brief stress management intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 27139783

Group type: EXPERIMENTAL
Intervention: Baseline ABI
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Change in ABI
Number of subjects: 812
Study: 25260025

Group type: EXPERIMENTAL
Intervention: 24-week version of the behavioral weight management program
Number of subjects: 162

Group type: COMPARATOR
Intervention: 12-week version of the behavioral weight management program
Number of subjects: 162
Study: 22352509

Group type: EXPERIMENTAL
Intervention: Vocoders that simulated aspects of cochlear implant processing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Recorded vowel‐consonant‐vowel tokens
Number of subjects: 38
Study: 20587720

Group type: EXPERIMENTAL
Intervention: LRYGB with omentectomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: LRYGB alone
Number of subjects: 22
Study: 18689361

Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (31% complex carbohydrate, 24% MUFAs)
Number of subjects: 12
Study: 15778880

Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg/day for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11836593

Group type: COMPARATOR
Intervention: Intravesical instillation of anticancer drug alone (method A)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intravesical instillation plus oral chemotherapy (doxifluridine, 5'‐DFUR) (method B)
Number of subjects: 196
Study: 10362181

Group type: EXPERIMENTAL
Intervention: Active counterpulsation (active CP)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Inactive counterpulsation (inactive CP)
Number of subjects: 139
Study: 8750168

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/d for 1 week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enprostil (35 microg/d for 1 week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin stimulation test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGE2 mucosal generation
Number of subjects: 0
Study: 1897264

Group type: COMPARATOR
Intervention: Western therapy (dihydrochlorothiazide and atenolol)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chinese traditional therapy (mixtures of nine herbs and other ingredients)
Number of subjects: 50
Study: 6275999

Group type: EXPERIMENTAL
Intervention: Cefotaxime alone (125 patients)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Gentamicin/clindamycin (124 patients)
Number of subjects: 249
Study: 31471753

Group type: EXPERIMENTAL
Intervention: Low-dose CT angiography using ASiR-V
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard CT angiography
Number of subjects: 80
Study: 31361682

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 42
Study: 28113240

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery over 12 weeks
Number of subjects: 8
Study: 26735385

Group type: EXPERIMENTAL
Intervention: Community health workers (CHW) trained to promote physical activity during home visits
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 176
Study: 24982375

Group type: EXPERIMENTAL
Intervention: 25 mg doxorubicin loaded Super Absorbent Polymer microspheres
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin loaded Super Absorbent Polymer microspheres
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 75 mg doxorubicin loaded Super Absorbent Polymer microspheres
Number of subjects: 25

Group type: COMPARATOR
Intervention: 0 mg (bland embolic)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bland embolic vs drug-loaded groups
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 25
Study: 22217100

Group type: EXPERIMENTAL
Intervention: Caffeine (600 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (20 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 19174719

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation for diabetic macular edema
Number of subjects: 323

Group type: COMPARATOR
Intervention: Baseline characteristics (CSMT, age, fluorescein leakage)
Number of subjects: 323
Study: 17845167

Group type: EXPERIMENTAL
Intervention: 0.5% malathion gel (30 minutes application)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Ovide Lotion (0.5% malathion)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Nix Crème Rinse (1% permethrin)
Number of subjects: 172
Study: 15447735

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once a day for four days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11678783

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 ml, double strength, three times a day for 2 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 9834260

Group type: EXPERIMENTAL
Intervention: SR27417A (10 mg/day)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 7912044

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (100, 30, and 6 ng.kg‐1.min‐1 for 10 min, 15 min, and thereafter, respectively)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 14
Study: 2732065

Group type: EXPERIMENTAL
Intervention: Family-based cardiovascular disease risk reduction intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study: 1103617

Group type: EXPERIMENTAL
Intervention: Inline, 0.45‐mum membrane filter
Number of subjects: 146

Group type: COMPARATOR
Intervention: Unfiltered fluids
Number of subjects: 146

Group type: COMPARATOR
Intervention: Buffered infusion fluid or 24-hour change of administration set
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with inline filters
Number of subjects: 146
Study: 31202024

Group type: EXPERIMENTAL
Intervention: 11-step stair climb test (11-SCT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Descending stair time during the 11-SCT
Number of subjects: 57
Study: 27376875

Group type: EXPERIMENTAL
Intervention: Autosuggestion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no autosuggestion)
Number of subjects: 60
Study: 26203826

Group type: EXPERIMENTAL
Intervention: 120 mg tabalumab every 4 weeks (120/Q4W)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: 90 mg tabalumab every 2 weeks (90/Q2W)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1004
Study: 24113125

Group type: EXPERIMENTAL
Intervention: Low-frequency (LF) rTMS (≤ 1 Hz) applied to the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 249

Group type: COMPARATOR
Intervention: High-frequency (HF) rTMS (10‐20 Hz) applied to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 249
Study: 21298412

Group type: EXPERIMENTAL
Intervention: Antecedent hypoglycaemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Euglycaemia
Number of subjects: 16
Study: 19187638

Group type: EXPERIMENTAL
Intervention: NTRK3 mRNA levels in TOF group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NTRK3 protein levels in TOF group
Number of subjects: 30
Study: 16481387

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (daily doses of </=500 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal corticosteroids
Number of subjects: 0
Study: 15170517

Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan haemorrhoidectomy (group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ferguson haemorrhoidectomy (group B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study: 11595086

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) applied in 300 ms intermittent pulses at 40 Hz, 15-20 mA for 8 hours a day up to 14 days of coma
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 10
Study: 9840852

Group type: EXPERIMENTAL
Intervention: Retrobulbar block
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subconjunctival bupivacaine infiltration
Number of subjects: 30

Group type: COMPARATOR
Intervention: No block (control)
Number of subjects: 30
Study: 7986147

Group type: EXPERIMENTAL
Intervention: Blood transfusions (allogeneic, autologous, or both)
Number of subjects: 420

Group type: COMPARATOR
Intervention: No blood transfusions
Number of subjects: 420